| 1 |
32779125 | Expression of aquaporin-2 in the collecting duct and responses to tolvaptan. | 2021 Feb |
3 |
| 2 |
34514204 | Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD. | 2021 Sep |
7 |
| 3 |
34955900 | The Role of Vasopressin V2 Receptor in Drug-Induced Hyponatremia. | 2021 |
1 |
| 4 |
28984014 | Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis. | 2018 Feb |
2 |
| 5 |
28090051 | Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome. | 2017 |
2 |
| 6 |
28326667 | The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment. | 2017 Sep |
5 |
| 7 |
26610908 | Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. | 2016 Jun |
7 |
| 8 |
26742881 | Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure. | 2016 |
7 |
| 9 |
26784173 | Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure. | 2016 Jan 14 |
4 |
| 10 |
26921537 | Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome. | 2016 May 1 |
1 |
| 11 |
24954239 | Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. | 2014 |
2 |
| 12 |
25318553 | Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure. | 2014 |
2 |
| 13 |
25318555 | Aquaporin-2-guided tolvaptan therapy in patients with congestive heart failure accompanied by chronic kidney disease. | 2014 |
1 |